Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Ferrata Storti Foundation
2014-11-01
|
| Sarja: | Haematologica |
| Linkit: | https://haematologica.org/article/view/7198 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|